Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -821.6%
Net margin was -821.6% in Q1 FY2026, down 222.9 pp from a year earlier. On a trailing-twelve-month basis it was -558.2%, down 235.2 pp year over year. Over 3 fiscal years it narrowed by 375.2 pp.
Context
- Net margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 9 analysts of -584.2% for the fiscal year ending Dec 2026, down from -513.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -821.6%-333.7 pp QoQ
- Last fiscal yearDec 2025
- -513.2%-209.5 pp YoY
- LTMMar 2026
- -558.2%-235.2 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -513.2%
- Year-over-year change
- -209.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -513.2% | -209.5pp |
| FY2024 | 2024-12-31 | -303.7% | -165.5pp |
| FY2023 | 2023-12-31 | -138.1% | -0.2pp |
| FY2022 | 2022-12-31 | -138.0% | -122.9pp |
| FY2021 | 2021-12-31 | -15.1% | — |
Net Margin vs competitors
How OCUL compares with its peers on the latest reported figures
- OCUL's LTM Mar 2026 net margin of -558.2% is the 5th highest of the 9 companies compared; the peer median is -818.0%.
- Its year-over-year change of -235.2 pp is the 5th highest of 8, against a peer median of -9.3 pp.
- Over three fiscal years its change of -375.2 pp compares with a peer median of -4.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -3.2% | +2.4 pp | -7.2 pp | |
| LTM Mar 2026 | -5.6% | +4.6 pp | +14.0 pp | |
| LTM Apr 2026 | -7.2% | +18.2 pp | -47.5 pp | |
| LTM Jun 2026 | -30.7% | -9.3 pp | -1.9 pp | |
| LTM Mar 2026 | -558.2% | -235.2 pp | -375.2 pp | |
| LTM Mar 2026 | -1605.2% | -334.1 pp | +1951.5 pp | |
| LTM Mar 2026 | -3566.6% | -3304.7 pp | -492.4 pp | |
| LTM Mar 2026 | -18297.5% | -30712.4 pp | — | |
| LTM Mar 2026 | -18861.3% | — | — | |
| FY2025 | — | — | — | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding OCUL) | -818.0% | -9.3 pp | -4.6 pp | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M |
| Cost of Revenue | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | 39.12M | 46.95M | 53.16M | 58.1M | 45.25M |
| Gross Margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Research & Development | 50.08M | 53.46M | 61.06M | 127.64M | 197.1M |
| Selling, General & Admin | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M |
| Operating Expenses | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| EBITDA | 2.54M | (61.91M) | (66.42M) | (176.14M) | (249.78M) |
| EBITDA Margin | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| Operating Income | (78.04M) | (78.65M) | (82.38M) | (171.78M) | (270.02M) |
| Operating Margin | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| Interest Income | 33K | 798K | 3.98M | 20.28M | 18.36M |
| Interest Expense | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M |
| Other Income / Expenses | 71.48M | 7.62M | 1.65M | (21.73M) | 4.08M |
| Income Before Tax | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Pre-Tax Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Net Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| EPS (Basic) | (1.05) | (1.04) | (1.09) | (1.22) | (1.42) |
| EPS (Diluted) | (0.98) | (0.97) | (1.02) | (1.22) | (1.42) |
| Weighted Avg Shares | 76.39M | 76.88M | 79.83M | 158.27M | 187.24M |
| Weighted Avg Shares (Diluted) | 82.16M | 82.64M | 85.6M | 158.27M | 187.24M |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.